Precision BioSciences' Response to CELLECTIS SA Lawsuit

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. today reacted to a patent infringement lawsuit filed by Cellectis SA, of Romainville, France. Precision’s management described Cellectis’ allegations as unfounded and stated that no such infringement has occurred. “Precision has reviewed Cellectis’ patent claims. It is clear that our next-generation genome engineering technology is demonstrably distinct from the dated technology covered by Cellectis’ patents,” said Matthew Kane, CEO of Precision BioSciences. “This lawsuit appears to stem from a fundamental misunderstanding of Precision’s DNE technology and how it is employed. Our DNE technology is the new gold standard in genome engineering and does not make use of the methods claimed by Cellectis.” In response to the lawsuit, Precision has engaged WilmerHale, a law firm with one of the nation’s premier intellectual property litigation groups. Mr. Kane concluded, “We deny any wrongdoing and will vigorously defend ourselves against any efforts to stifle the lawful practice of our cutting-edge DNE technology.”